Topic: inter partes review
Dealing a blow to branded drugmakers, the U.S. Supreme Court found that inter partes review patent challenges are constitutional.
Allergan took all kinds of criticism for its tribal licensing deal, but an appeals court decision has breathed new life into the strategy.
After a Friday ruling, Allergan's eye drug Restasis has to face the very patent challenge the company sought to prevent.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Allergan CEO Brent Saunders said it was "tenacity," not "desperation," that led the company to enter into the tribal licensing deal.
Allergan inked a settlement that gets one more would-be generic challenger off its radar, for now.
Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.
Sen. Claire McCaskill is moving to shut down the "brazen loophole" exposed in Allergan's tribal licensing deal.
Sanofi and Regeneron have gone the IPR route in their attempts to stop Amgen's patent infringement case over Dupixent. And so far, it hasn't worked.
Allergan is again being accused of using unfair tactics to dodge competition for its eye drug Restasis, this time for using bundled contracts.